GIANTT

Groningen Initiative to ANalyse Type 2 diabetes Treatment...

Description

Dynamic cohort with routinely collected prescription and diagnostic data for people with type 2 diabetes mellitus...

General Design

Type
Cohort study
Cohort type
Clinical cohort
Data collection type
Retrospective, Prospective
Design
Longitudinal
Design description
Dynamic cohort of T2DM patients from various general practices
Start/End data collection
2004 (ongoing)
PID
https://doi.org/10.34760/652666d663240

Population

Countries
Netherlands (the)
Regions
Groningen
Number of participants
64000
Number of participants with samples
0
Population age groups
Adult (18+ years)
Main medical condition
  • IV Endocrine, nutritional and metabolic diseases

Organisations

Lead organisations

Contributors

  • prof. dr.  PD (Petra) DenigUniversity Medical Centre Groningenp.denig@umcg.nl

    Principal Investigator, Primary contact

Available Data & Samples

Data categories

Medical records

Areas of information

  • Socio-demographic and economic characteristics
  • Medication and supplements
  • Physical measures and assessments
  • Laboratory measures

Subpopulations

List of subpopulations for this resource...

Collection events

List of collection events defined for this resource...

Access conditions

Request for use must be approved by steering committee....

Data access conditions
health or medical or biomedical research
Data use conditions
  • project specific restriction
  • return to database or resource
Data access fee
true
Release type
Periodically
Release description
Request to be assessed by GIANTT steering committee
Linkage options
No linkage options.

Funding & Acknowledgements

Acknowledgements
This research has been conducted using anonymous data collected from the Groningen Initiative to ANalyse Type 2 diabetes Treatment (GIANTT) database (www.giantt.nl). This longitudinal database contains data from electronic medical records, including prescription data, comorbidity and event data, routine laboratory test results and physical examinations, for patients with type 2 diabetes managed in primary care in the north of the Netherlands (<1% opted out). In The Netherlands, no approval of an ethics committee is needed for studies using anonymous data from medical records.

Documentation